Expectations trend
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsNASDAQFinancialsBanks - RegionalSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BAFN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Completion and success of private placement and securities registration | A supporting condition in Bayfirst Financial Corp's published investment case. The stated target is Successful registration and resale of shares. | Improving | Private placement or registration fails or harms capital structure | Qualitative: Rights offering at $3.50 for 4.1M shares (Aug 2026) and Q3 NIM 4.07% vs target of successful registration/resale August rights offering for 4.1M shares and Q3 NIM of 4.07% confirm capital allocation progress. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
BAFN is a potential turnaround, meaning its thesis depends on repairing weak results rather than extending a proven record of growth. The thesis is on watch: performance remains weak and below its industry cohort, despite a recent improvement in the management score.
The valuation evidence points in two directions: BAFN is described as cheap versus peers, but also carries a 17% premium versus peers. The expectations gap is negative, which suggests expectations are already demanding; confidence in this assessment is medium, and the evidence does not explain the measures behind these differences.
Near term, results are still weak and the company remains loss-making. Management’s priorities are to resolve the legacy SBA 7(a) loan portfolio, return to profitability, and expand community banking, but all remain at the watch stage. A guidance cut would add pressure, while lower interest rates are a stated risk for financial companies.
The multi-year thesis hinges on whether management can resolve the legacy loan portfolio and restore profitability. Near-term guidance is a key swing factor; stronger results and guidance from sector bellwethers could also support sector momentum, while rate cuts could weigh on the sector.
Over the next 1 to 3 years, BAFN remains a high-risk, unproven recovery story, with weak results and execution on its stated priorities central to the thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful CEO transition to Alfred T. Rogers, Jr. | A primary condition in Bayfirst Financial Corp's published investment case. The stated target is Stable leadership and progress in CEO transition. | Improving | CEO transition fails to stabilize or improve company performance | NIM 4.07% vs qualitative target Q3 NIM 4.07%, rights offering for growth, former CEO board departure, neutral CFO agreement changes. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of about 0.55% in 2026 | A primary condition in Bayfirst Financial Corp's published investment case. The stated target is 0.55% revenue growth. | Intact | YoY revenue growth falls below 0.4% in FY26 | Revenue growth: -27.28% FY2026-Q2; GAAP. Published target: 0.55% revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-27.282826 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.